MedPage Today on MSN16d
Safer Antiplatelet Routines, Non-Statin Meds Feature in New Heart Attack GuidelinesIn updated American recommendations for the management of acute coronary syndrome (ACS), bleeding reduction strategies on antiplatelet therapy are embraced, as are non-statin lipid-lowering therapies ...
Poor performance on quality metrics carried greater risk of in-hospital mortality no matter where patients initially ...
The American College of Cardiology (ACC) and the American Heart Association (AHA), in collaboration with other societies, released a full guideline on the management of patients with ACS on Thursday, ...
More importantly, and less well described in the literature, is how this risk:benefit ratio plays out for patients with NSTEMI or for patients with ACS. As in the case of STEMI, the outcome of DES ...
The American College of Cardiology and the American Heart Association today released an updated clinical practice guideline for managing individuals experiencing acute coronary syndrome (ACS). The ...
STEMI is an ACS, involving an unstable atherosclerotic plaque and thrombosis. Other disorders may cause chest pain symptoms and ischemic ST segment elevation on the ECG, but are not caused by ...
When an ACS with intra-coronary thrombosis occurs ... Two distinct treatment pathways exist for the treatment of unstable angina/non-STEMI: the “early invasive” strategy and the “ischemia ...
and ST segment elevation myocardial infarction (STEMI). There can be some variation as to which forms of MI are classified under acute coronary syndrome. ACS should be distinguished from stable ...
Following cardiac catheterization, patients with ST-segment elevation myocardial infarction (STEMI) have a higher risk of short-term mortality than patients with non-STEMI (NSTEMI), who have a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback